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Background: Cervical cancer (CC) remains a leading cause of gynaecological cancer-related mortality worldwide. CC
pathogenesis is triggered when human papillomavirus (HPV) inserts into the genome, resulting in tumour suppressor gene
inactivation and oncogene activation. Collecting tumour and blood samples is critical for identifying these genetic alterations.
Methods: BIO-RAIDs is the first prospective molecular profiling clinical study to include a substantial biobanking effort that used
uniform high-quality standards and control of samples. In this European Union (EU)-funded study, we identified the challenges that
were impeding the effective implementation of such a systematic and comprehensive biobanking effort.
Results: The challenges included a lack of uniform international legal and ethical standards, complexities in clinical and molecular
data management, and difficulties in determining the best technical platforms and data analysis techniques. Some difficulties were
encountered by all investigators, while others affected only certain institutions, regions, or countries.
Conclusions: The results of the BIO-RAIDs programme highlight the need to facilitate and standardise regulatory procedures, and
we feel that there is also a need for international working groups that make recommendations to regulatory bodies, governmental
funding agencies, and academic institutions to achieve a proficient biobanking programme throughout EU countries. This
represents the first step in precision medicine.
Cervical cancer (CC) remains the fourth leading cause of cancer-
related deaths in women worldwide (Ferlay et al, 2015), and there
have been no marked therapeutic innovations in recent decades.
A recent review found only minor improvements in survival across
cancer types (Prasad, 2016), despite the fact that more than 70 new
cancer drugs were approved by the FDA between 2002 and 2014.
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Nonetheless, some recent drugs, particularly when used
in combination, showed promising results in selected cancers
(Furue and Kadono, 2016). Many precision medicine trials are
currently ongoing; they involve (1) the addition of targeted
therapies to standard therapies according to specific single
molecular alterations and/or tumour types and (2) algorithm
testing in late-stage tumour types (Le Tourneau et al, 2014). The
latter programs imply well-defined biobanking procedures for
tumour, blood, sera and blood collection a prerequisite for precise
and reproducible molecular results. Feedback on prospective
biobanking experiences and challenges are starting to be reported
with relevant standard operating procedures (SOPs; Diaz et al,
2013; Riondino et al, 2015). Results, available from the prospective
‘SHIVA’ trial conducted at the Institut Curie, turned out negative
for the primary endpoint. Single drug usage in advanced disease is
thought to be a reason for this overall negative result. However, it
was concluded that administration of targeted therapies in late-
stage patients, used outside of their usual indications, might still be
a valid approach to prolonging disease-free survival in subgroups
of patients, in particular those harbouring a molecular alteration in
the MEK/RAF signalling pathway (Le Tourneau et al, 2015).
We have focused on CC, where biopsies can be easily obtained.
Molecular studies of CC are relevant for evaluating cancer
pathogenesis as a dynamic multistep process that includes
continuous genetic diversification, clonal expansion and selection.
Essential genetic alterations in CC (and to 1/3 of HNSCC) are
virtually always kicked off by the insertion of pathogenic
HPVs leading to abnormal activation of oncogenes and/or the
inactivation of tumour suppressor genes. These alterations can
be detected using a range of techniques (Le Tourneau et al, 2016).
The International Cancer Genome Consortium (ICGC) studied
more than 25 000 cancer genomes from patients with 50
different cancer types and identified the most frequent gene copy
number variations, translocations, and point mutations to
determine those that can be considered ‘druggable’ therapeutic
targets (International Cancer Genome et al, 2010). When we
started this clinical trial, no prospective data set studying the
relevance of molecular alterations in CC outcome was available.
Owing to the well-known high intra-tumour heterogeneity of
genetic alterations, there have been few recent clinical break-
throughs in any cancer. It has been suggested that neo-antigens,
which potentially influence immune surveillance, may arise in
parallel with genetic alterations (Marusyk et al, 2012; McGranahan
et al, 2016), presenting opportunities for immunological targeting.
Although treatment using molecular stratifications has not been
attempted systematically in CC, differential mutational and gene
expression patterns are associated with squamous or adenocarci-
noma CC histopathological types (Schwarz et al, 2012; Scholl et al,
2013; Jimenez-Wences et al, 2014; Ojesina et al, 2014; Rusan et al,
2015; Spaans et al, 2015). In retrospective data sets of CC and head
and neck tumours combined, three subgroups of pathway
alterations were revealed in human papillomavirus (HPV)-
associated cancer: namely cell proliferation/survival, immune
response/cell death, and cellular differentiation (Rusan et al, 2015).
BIO-RAIDs, a prospective study of patients with previously
non-treated CC (stages IB1–IV), was initiated in seven European
countries with the aim of analysing primary tumours at the
molecular level along with patient outcome to stratify tumours into
classes according to the underlying pathway activation and
prognosis. Preliminary bioinformatics analysis using ACSN (Atlas
of Cancer Signalling Networks), which was based on TCGA,
Ojesina (Ojesina et al, 2014) and the first exome sequencing data
from the first 48 BIO-RAIDs patients, suggested that CC can be
stratified into 5 classes with distinct molecular features (unpub-
lished data). At the time of manuscript submission, BIO-RAIDs
had recruited over 400 patients. The BIO-RAIDs protocol was
published previously (Ngo et al, 2015).
Here we present the challenges for molecular assessment studies
that were identified during this systematic biobanking and provide
recommendations for conducting similar studies in the future.
The identified challenges were related to: diversity of legal and
ethical standards in different countries, lack of clinical trial
resources at some centres, lack of experience in biobanking in
many centres, and to the complexity integrating molecular data on
multiple samples (Figure 1). Clear guidelines are needed to
perform a coherent and reproducible molecular analysis of
tumours and to guide appropriate clinical trials. Our hope is that
BIO-RAIDs will set the stage for future precision medicine studies
by international groups.
CHALLENGES AND SUGGESTED RECOMMENDATIONS
FOR FUTURE BIOBANKING STUDIES
Delays in regulatory approval before the initiation of clinical
trials. One of the major challenges encountered was that the study
protocol was perceived differently by the participating European
countries, and variations in regulatory aspects in the countries
involved complicated the initiation of the clinical trial (Table 1). In
some countries, BIO-RAIDs was considered an interventional
study due to the request for iterative biopsies and blood sampling.
In contrast, other countries considered it a non-interventional
study since it did not modify standard treatment procedures. This
classification impacted insurance fees and caused delays in
contracting. Furthermore, in some countries, any biobanking study
requires clinical study insurance, regardless of whether it is labelled
‘interventional’. Insurance costs vary according to the number of
patients, the risk of participating in the study, and protocol
timelines. The variations in insurance fees were quite large, despite
leverage between insurance agencies, and in particular the costs
depended on whether the insurer had to insure patients outside of
his home country. The timelines for contract negotiation between
Sponsors (or Sponsor Delegates) and the different clinical sites
depended on approval by the Boards of Directors of the hospitals
involved. Protracted discussions about the types of responsibilities
that were delegated to Sponsors or Sponsor Delegates included a
detailed scrutiny of all monitoring tasks to minimise person-
months and therefore costs. One issue was the definition of the lieu
to settle disputes in court and the absence of an established
international rule concerning this matter. For BIO-RAIDs, it was
decided that any dispute would be settled in accordance with the
national law in the defendant’s country. Lengthy procedures for
reimbursing subcontracted tasks by administrations in high-
income countries to contract research organisations in lower-
income countries were discouraging for both the clinical
investigators and for the subcontracted support structures.
Recommendations for speeding up clinical trial initiation.
Clearer European guidelines and common legislation would be
helpful for future prospective studies that are ‘without an
experimental drug’. The new European regulation, European
Union (EU) No. 536/2014, provides some modified regulatory
requirements for low-interventional trials. Similar directives are
urgently needed for biobanking studies which have minimal or no
added risk for the patients. Sampling and biobanking are routine
procedures in qualified hospitals and might ideally be part of the
institutional coverage. The need for additional insurance for
biobanking leading to targeted therapy trials should be examined
further. Standard European guidelines for contracting between
partners in clinical trials would be advantageous. Both operational
and financial autonomy for heads of clinical support structures in
larger hospitals/scientific administrations is important to expedite
the implementation of new trials and reduce the time-to-site
initiation.
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Site-specific logistics in different European countries. Routine
biobanking with clinical annotation and SOPs for tissue handling is
relatively new for most sites, and takes time to set-up and to make
it efficient (Table 2). BIO-RAIDs identified the following issues
that might cause delays: site-specific logistics; organisational issues,
such as the availability of experienced investigational personnel;
access to liquid nitrogen, and sampling logistics; and the quite
variable experience of each site in terms of conducting clinical
trials. In some countries, imaging procedures for staging, such as
MRI, mandatory to assess a primary endpoint of response to
standard therapy were not routinely available. The lack of cohesion
between regional and national requirements for imaging type
Table 1. Delays in regulatory approval before the initiation of clinical trials
Challenges Specific challenges Recommendations
Management of
clinical study
Regulatory qualification Interventional
France, Serbia
Common EU rules for biobanking in academic clinical
studies (solved in new EU ruling)
Non-interventional
The Netherlands, Moldova, Germany and Romania
Clinical site selection Pre-study visits and qualification of sites:
investment of manpower and budget: time
consuming and costly
Develop stringent site selection criteria a priori
Provide clinical research assistance in countries with high
patient volume but little clinical trial experience
Use pre-existing network
Clinical protocol Serious adverse event regulations vary as a function
of interventional/ non-interventional definition
Country-specific variations to be added in a national
addendum to the protocol Protocol harmonisation for all
EU countries
Trial insurance High inter centre variability in cost International EU guidelines for trial insurance
Abbreviation: EU= European Union.
Table 2. Site-specific logistics in different European countries
Challenges Specific challenges Recommendations
Management of
clinical study
Clinical trial
management
structures
Centre specific variations in experience in international trial
conduct. Difficulty to recruit experienced clinical trial support
personnel in a short period of time, for a defined and limited
time span
Mitigating workload between national and international
clinical trials support structures
Clinical readout MRI: objective
endpoint
Cost of optimal imaging techniques which are not routinely
performed in all participating countries but mandatory for
evaluation of primary endpoint
Discuss shared cost basis with health insurance in an
academic clinical trial involving biobanking without
investigational new reagent
Abbreviation: MRI¼magnetic resonance imaging.
Site-specific logistics
Clinical centres initiation and
activation
Clinical data & sample collection
and monitoring
Molecular laboratory technologies
(NGS, RPPA, IHC)
Data integration, quality control
and data analysis procedures
Patient
with CC
Patients stratification
& new therapeutic
interventions
Figure 1. An overview of the critical challenges for performing prospective biobanking studies.
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(CT rather than MRI) at some sites became apparent when the
BIO-RAIDs study began.
Recommendations for improving site-specific logistics. Although
an evaluation of study feasibility must focus on the availability of
dedicated management personnel who can coordinate logistics and
facilitate local management of the study, it must also investigate
sites that have a high patient recruitment potential but few or
absent dedicated management personnel. We recommend that
sites strive to hire experienced management staff in sufficient
numbers and train local staff. If this cannot be achieved, regardless
of the reasons, the site should be barred from participation until its
issues can be resolved.
Site performance is also largely dependent on the principal
investigator’s (PI’s) dedication and availability. If the PI moves to a
different workplace or is unavailable for a protracted time, it can
jeopardise patient recruitment and the ability of the site to conduct
the study. Both the PI and an actively participating proxy should be
involved in the trial from the start. If biobanking with clinical
annotation is new or relatively new to a site that is otherwise
experienced in clinical trial conduct, we advise sending experienced
staff to the specific site to assist with the initial set-up and to
provide tools for handling biobanking. Finally, international
TripAdvisor-like public ratings of site performance might help
facilitate necessary changes and improvements.
Collection and monitoring of clinical data and samples. A
number of prognostic factors have been put forward for CC (Monk
et al, 2007; Rose et al, 2015; Pelkofski et al, 2016), virtually all data
have been identified retrospectively, often from small patient
populations (Table 3). The prospective assessment of prognosis
allowing the comparison of lifestyle and clinical parameters with
molecular patterns and outcome is of great interest to clinicians.
This prompted us to develop an electronic case report form (eCRF)
that required a major effort from clinicians and clinical trial
investigators to (a) gather and fill in the data and (b) to control the
data in source documents. Our initial version of the eCRF turned
out not to be sufficiently user friendly for clinicians and clinical
monitoring personnel and needed to be simplified.
In an attempt to reduce shipping costs, barcoded samples were
sent in small batches to national referral centres, reviewed for
missing samples and sent on in larger batches to the reference
laboratory.
With over 400 patients registered at the time of submission,
more than 5000 samples consisting of tumour (fixed and frozen) at
baseline (and in case of residual tumour or progressive disease
secondary biopsies at a later stage) together with whole blood,
serum (baseline, post treatment, and 6 monthly) have been at this
point transferred to a centralised laboratory at Erasmus, Rotterdam
for quality control (QC). QC reviewed pathological diagnosis and
evaluated tumour cellularity (430% for full exome, 10–30% for
targeted panel) from the first and last slice of each set of tissue
slices sent for molecular assessment.
All errors which occurred were human errors, the most serious
one being a mislabelling by the carrier company, sending a batch to
the wrong country. The late recognition of errors (inversion of
labels for blood and serum) proved labour-intensive to correct. A
central integration platform in knowledge data integration (KDI)
at Institut Curie continuously checks for incoherences in the data,
sending out reports to all laboratories and clinical monitoring
groups. Incoherence in sample ID is checked first. The EAN-13
barcoding scheme was used for sample labelling in the BIO-RAIDS
study. Although this format includes a built-in error-checking
capability, it could only code for numeric values. Thus, when these
barcoded sample IDs are imported into spreadsheet software
such as Libre Office or Microsoft Office or into the R statistical
computing environment, the 13 digit barcodes are routinely
recognised as huge numeric values and are transformed into
floating point numbers (for instance, 9110351350145 may be
converted to 9.110351eþ 12 on import). Although it is possible to
circumvent this ID corruption in all of the relevant software
products, the import of EAN-13 barcodes that only contains
digits still requires special attention. Data import issues related
to the EAN-13 barcodes can easily be avoided by using both
letters and digits. Such ‘import-safe’ barcodes require appropriate
symbology, for example, code 128 that can encode all 128 ASCII
characters while offering a built-in checksum system similar to that
of EAN-13.
Incoherencies in sample preparation (fixed instead of frozen) or
tissue type (tumour, formalin-fixed paraffin-embedded (FFPE),
and serum) could be corrected by inspection since the colour of the
material in the tube allows to distinguish between FFPE fixed
tumour and serum; equally blood and serum are distinguishable by
inspection. We implemented a monthly report allowing high-
lighting the incoherences and making the necessary corrections.
The only way to control the biobanking common information was
to cross-check the biobanking annotations of sample ID and data
of sampling used in each platform against information received
from Erasmus and Quanticsoft.
Recommendations for timely sampling and for controlling
sampling logistics and clinical data. For effective biobanking
(that is, sample handling, shipping, and storage), we feel that
sample sets from each patient should ideally be sent promptly to a
fully accredited central biobank that will check that the sample is
present and send a feedback on the quality of each sample in real
time. The biobank should send out electronic alerts to centres
when repeat sampling procedures are coming up with copies to the
clinical monitoring personnel. Yet this needs to be cautiously
evaluated in terms of costs.
Clinical data collection and monitoring tasks can be simplified if
we adhere to the following principles. First, the data to be collected
should be limited to data relevant for evaluating the study
Table 3. Collection and monitoring of clinical data and samples
Challenges Specific challenges Recommendations
Biobanking Logistics of tissue
sampling and SOPs
Logistics of sites: regular supply of liquid nitrogen, tubes,
trained personnel, control of temperatures, and
traceability
Provide all clinical centres with barcode readers.
Regular visits to sites and extensive control checks on samples.
Regular monthly teleconferences to inform on progress.
Develop international network of integrated ISO labelled
biobanks with clinical support structure
Management
of clinical study
Barcode design
and eCRF capture
Information extraction for sample(s) and traceability
during shipment
eCRF development to involve information technology
developer, clinicians, scientists and clinical research
support team knowledgeable in informatics. Development
of user-friendly electronic tools
Liquid biopsy Repeat sampling Regular 6 monthly serum sampling needed for efficient
statistical assessment of relevance to outcome
Electronic recall in anticipation of repeat sampling by pop
up window in eCRF and in electronic patient file
Abbreviations: eCRF¼ electronic case report; SOP¼ standard operating procedures.
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objectives. Second, the data should be captured in real time using a
validated, user friendly eCRF to facilitate flawless data collection
and integration. Third, the accuracy, completeness, and coherence
of the entered data should be assured through eCRF internal
controls. This allows a considerable reduction in on-site monitor-
ing time and therefore a reduction in monitoring costs. The eCRF
should include an interactive biobanking section that is accessible
to and completed by the clinical centres as well as by the central
molecular laboratories to ensure traceability and future use of
samples in subsequent ancillary studies. WEBTRIAL was used for
the BIO-RAIDs study. Many other easy-to-use eCRF backbones are
available today, such as Marvin, REDcap, which is a free, web-
based, user friendly electronic data capture (EDC) tool for research
studies. The monitoring strategy should ideally be described in the
monitoring plan, and significant steps that are meant to reduce the
cost of monitoring should be considered. It is currently estimated
that the use of complete source data verification will not necessarily
result in a substantial improvement in study data. Rather, a risk-
based approach for QC, including on-site monitoring, should focus
on the study procedures and data, which are relevant for patient
safety and data integrity. The following suggestions by Messenger
et al (2012) might be worth exploring further: (1) issue a QC report
for the data; (2) have a set of internal quality-assurance controls
embedded in the eCRF; and (3) institute a yearly data audit
programme that includes biobanking information that can
be applied to non-interventional studies. Finally, the QC and
monitoring strategies should be discussed initially with all
participating partners, for example, with clinicians, data manage-
ment personnel, and biostatisticians.
Optimal sampling and choice of molecular technologies
Sampling procedures. A variety of challenges are associated with
the molecular screening of solid tumours, the first being the
collection of adequate samples for the selected molecular technique
which dictates the specific handling of tissue samples (Table 4).
Cervical tumours are generally easier to access than other
cancers, but it should be kept in mind that all biopsies are
just a fragment of an observed lesion. Therefore a single tumour
biopsy sample is likely to grossly underestimate intra-tumour
heterogeneity (Gerlinger et al, 2012; Swanton, 2012). Conversely, a
mutational signal can be difficult to detect due to normal tissue
‘contamination’ that may be present in greater amounts than the
tumour cells. Central pathology review appears mandatory. At the
reference lab a well-trained technician and a qualified pathologist
routinely check, next to histology, the percentage of tumour cells in
each biopsy. For this, morphology is taken into account, meaning
that next to the percentage of tumour cells the contribution of the
infiltrating cells are taken into account resulting in a weighted
estimate of the percentage of tumour cells for DNA analyses. Cut
offs of o10%, 10–30%, and 430% are used.
Molecular analysis techniques. A number of techniques can be
used to assess DNA, RNA, and protein alterations in cancer. Our
goal was to use validated assays that give reproducible results
which lead to treatment recommendations (Le Tourneau et al,
2016). BIO-RAIDs assesses several such techniques. (1) Genetic
alterations (genomics) were investigated using next generation
sequencing (NGS; full exome of 100 patients), and the resulting
information was used to design and utilise a specific targeted panel
of genes for the remaining patients. (2) Specific protein pathway
activation (proteomics) was detected using reverse-phase protein
arrays (RPPAs), and (3) the tumour immune cell and microenvir-
onment interactions were investigated using immunohistochem-
istry (IHC). (4) There is a need for the development of ‘liquid’
biopsies and for the detection of surrogate biomarkers; therefore
we assessed circulating free DNA (cfDNA) levels and dedicated
mutations and HPV insertions. Circulating tumour cells are shed
into the bloodstream and can be detected with several technologies
(Alix-Panabieres and Pantel, 2014). (5) RNA-based tests (tran-
scriptomics) were not deemed feasible due to their higher cost and
because targeted drugs are more likely to act on protein targets.
However, residual frozen tissue samples are stored in a dedicated
biobank to allow academic RNA-based or epigenetic studies to be
conducted in the future.
Finally, of the multiple NGS techniques that are currently
available, whole-genome sequencing probably represents the most
comprehensive strategy for tumour genomic analysis. Due to high
costs and the current long turnaround time, its routine clinical use
remains limited. Whole-exome sequencing (WES) appears to be a
Table 4. Optimal sampling and choice of molecular technologies
Challenges Field Specific challenges Recommendations
QC Pathology 430% tumour cells: sample is suitable to be
assessed by full exome/genome sequencing
and by RPPA
o30% of tumour cells: sample can still be
assessed by targeted gene analysis
Compare results of key genetic alterations by full
exome and targeted analyses for their value in
predicting standard and innovative treatment
outcome
Rapid changes in
sequencing technologies:
Solid vs Illumina technology Library generation kits, sequencing kits are
constantly developed by manufacturers.
Updated kits are not 100% compatible with
previous releases and may introduce technical
bias to the data
Careful selection of platforms and kits to avoid
introducing technological heterogeneity
Identification and removal of any version-
dependent technical bias on the data set
Proteomics RPPA captures information on
phosphorylated proteins
retrospectively on complete
data set
Of high interest in clinical trials but not useful
for decision making in real time
Integration with genomic data, development of
suitable routine techniques (ELISA and IHC) for
prospective assessment of markers discovered
by RPPA
HPV serotypes and HPV
host integration sites
Action mechanism and
precise HPV contribution to
genetic reshuffling and
tumourigenesis
Integration site assessment by DIPS-PCR is
limited to HPV16 and HPV18 tumours only
Illumina sequencing permits integration
studies of all HPV types
Compare both HPV integration site and HPV E7
sequence detection as markers and define which
one is the most sensitive
IHC Investigator dependant Standard IHC: inter assay variability and
difficulty to quantify results. Readout is
investigator dependant and costly
Rationalise information–use semi-automated
systems–multicolour imaging and scoring of 8
variables on the same slide–further testing
Abbreviations: DIPS-PCR=detection of integrated papillomavirus sequences by ligation-mediated PCR; ELISA¼ enzyme-linked immunosorbent assay; HPV= human papillomavirus; IHC¼
immunohistochemistry; QC¼quality control; RPPA¼ reverse-phase protein array.
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far more practical technique for routine clinical use, and WES has
been incorporated into patient selection strategies in clinical trials
(Roychowdhury and Chinnaiyan, 2014; Beltran et al, 2015). WES
was selected for use in the BIO-RAIDs study (n¼ 100) to
prospectively evaluate very diverse alterations, ranging from point
mutations to whole chromosomal rearrangements, and to detect
less frequent alterations that are relevant to patient outcome. BIO-
RAIDs is developing targeted exome sequencing of a panel of genes
that were chosen because they harbour hotspot mutations
according to both our own WES data and according to the
literature. Such a targeted panel offers several advantages; in
particular, it is cost- and time-effective, and it has manageable
bioinformatics and computational requirements (Roychowdhury
and Chinnaiyan, 2014; Dietel et al, 2015).
Sequencing instruments, library preparation kits, sequence
kits, and analytical tools are in constant development and are
likely to change during the course of a multi-year study. For
example, the Solid platform, which was the platform of choice
during early BIO-RAIDs discussions, had become obsolete by the
time the first patient samples were available. Thus, a series of
adaptations had to be made to the technical platform. In addition,
once the migration to the HiSeq Sequencing Systems was
complete, Illumina released a novel sequencing chemistry, V4,
that could handle more sequences per run and that had a longer
read length. However, detailed QC assessment later revealed that
the 125-bp V4 reads tended to show a sharp drop in sequencing
quality in the last 10–15-bp regions, while the 100-bp reads using
the previous V3 chemistry were much less affected by this
phenomenon. The effect of the drop in the quality of V4 reads on
the downstream analyses (such as somatic variant calling, copy
number estimations) is still under investigation and requires
changes in the computational pipelines.
Proteomics studies are needed to assess the functional relevance
of mutated genes that are identified by genomics technologies.
Proteins are highly dynamic molecules and are subject to extensive
functional regulation, most notably by post-translational modifica-
tions. In-depth studies of proteomic profiles will help us under-
stand CC tumour pathogenesis more comprehensively and could
lead to the identification of novel biomarkers and cancer therapy
targets (Sallam, 2015). RPPA is a high-throughput dot-blot
technology with two major advantages: first, it compares hundreds
of biopsies simultaneously on the same array; second, it requires
only small amounts of tissue. RPPA is therefore currently the
method of choice for retrospective targeted analysis of biopsies.
However, it is less well suited for prospective patient investigation
for clinical decision-making. Furthermore, RPPA technology is
targeted and therefore relies on the availability of high-quality
antibodies. The percentage of tumour cells in the tissue is also a
real issue. Laser capture microdissection can be used to enrich
tumour regions, but this is time-consuming and substantially
reduces the throughput. Finally, since post-translational modifica-
tion is highly dynamic and unstable, the freezing, storage, and
shipment conditions must be carefully controlled.
Immunohistochemistry provides a robust view of intra-tumour
heterogeneity and is crucial for confirming the genomic alterations
that are identified during genomic analyses. Furthermore, IHC is
useful for studying the interactions between tumour cells and the
host immune system. Unfortunately, standard chromogenic IHC
has inter-assay variability, so quantifying the results is difficult. The
main hurdle associated with IHC is linked to sample processing in
that the tissue must be adequately fixed in formalin. In addition,
standard IHC techniques are limited to the use of one specific
antibody of interest, and different laboratories use different
antibody clones.
Recommendations for tumour sampling and molecular
techniques. One key issue in the selection of the best analytical
technique is the availability of the appropriate type of sample, that
is, tumour (fresh, frozen, or fixed), blood, or plasma.
Analysing multiple tumour biopsies from different sites is ideal,
but can be logistically challenging. To ensure best quality sample
for nucleic acid extraction procedures, one or more samples must
be snap-frozen in liquid nitrogen and stored until analysis.
The other samples must be quickly fixed in neutral-buffered
formalin for pathological and molecular analyses. The aim
should be to keep a mirror FFPE tumour block of the tumour
area from which a frozen sample has been taken. Furthermore, a
frozen sample of peri-tumoural normal tissue should also be
obtained.
Molecular results are used to make treatment decisions and,
consequently, are subject to legal obligations that are designed so
that the tests are reproducible and adhere to high standards
ensuring sensitivity and specificity. Molecular platforms therefore
need to be validated. Despite the lack of clear guidelines, FDA-
certified platforms in the USA and ISO-certified platforms in
Europe are being developed (McShane et al, 2013).
To minimise the risk of technical bias in the data set, it is
highly desirable that every sample be processed using exactly the
same kits and methods. If the logistics and the project timing
allows it, and if the necessary instruments are available, it seems
worthwhile to first gradually collect the complete set of quality-
controlled DNA/RNA samples and then later to process them all
within a single wet lab project to ensure identical kit versions for
all of the analyses.
NGS or targeted digital PCR of cfDNA can be used to identify
changes in the tumour mutational landscape, and cfDNA can be
detected in the absence of CTCs (Bettegowda et al, 2014). Targeted
sequencing of cfDNA can detect driver mutations at low allele
frequencies with high sensitivity (Frenel et al, 2015). Such findings
could allow treatment monitoring and early detection of resistant
mutations before radiological signs of disease progression (Oxnard
et al, 2014). Notably, cfDNA can also be detected in other body
fluids, like saliva and urine (Janku et al, 2014; Wang et al, 2015).
Using NGS to detect circulating cfDNA, it is possible to indirectly
track tumour progression; moreover, mutations that were
identified in the tumour can be detected with a simple blood
sample (Lebofsky et al, 2015; Lianos et al, 2015). Since cfDNA can
originate from either the primary tumour or from a metastatic site,
it serves as a ‘liquid biopsy’ that reflects the genetic heterogeneity of
a patient and could potentially identify putative targets for therapy.
cfDNA also represents a way to monitor genetic heterogeneity
during treatment in a non-invasive manner. A recent paper
supports this, describing how diverse cancers show detectable
ctDNA alterations, with the majority being theoretically actionable
by approved agents (Schwaederle et al, 2016).
To reliably analyse protein modifications, the biopsy must be
flash-frozen in liquid nitrogen, ideally on-site at each clinical
centre. When there is no high-quality antibody available for a
protein of interest, a protein downstream in the same signalling
pathway can be utilised as a surrogate marker. Epithelial cell and
immune cell infiltrate markers can be added to the analysis and
might give a rough estimation of tumour content that can be
compared with the pathology results. In the future, other
technologies that overcome the difficulties of RPPA might be
sufficiently improved and affordable that they could be used in
clinical studies. Notably, rapid advances are being made in the field
of mass spectrometry, but data interpretation remains a challenge,
and large amounts of tissue are required to analyse the phospho-
proteome.
For IHC analyses, the development of technical SOPs, the use of
validated antibody clones, and specifically the use of (semi-)
automated systems will enable quantitative pathology assessments.
This field is currently taking a huge leap forward due to advances
in digital pathology and due to the rapid development of
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simultaneous multispectral analysis of many different markers
in one small biopsy, which will ultimately lead to its implementa-
tion in day-to-day pathology practice (Feng et al, 2015).
Therefore, objective, high-throughput biomarker quantification
and co-localisation using multiplexed IHC will aid in the future
selection of patients that might benefit from specific treatment
(Huang et al, 2013; Dixon et al, 2015).
Challenges in QC, data integration, and data analysis. Rapid
advances in technology have decreased costs and improved
throughput, allowing the collection of vast amounts of ‘omics’
information in cancer (Table 5). However, robust and reproducible
bioinformatics tools that can be used to interpret these data are still
being developed. NGS has paved the way for precision medicine in
the field of oncology. The lower laboratory sequencing costs of
NGS caused an exponential increase in the amount of data
produced, putting a large strain on data managers and bioinfor-
matics engineers who were called on to manage all of this
information (Simon and Roychowdhury, 2013). Collectively, NGS
and ‘omics’ techniques have huge potential for clinical applications,
but the techniques and tools are constantly developing. The
availability of high-throughput technologies dedicated to clinical
applications makes them very attractive for daily use in cancer
centres. However, establishing these clinical facilities is not a trivial
task due to the overwhelming amount of data. There are three
challenges in extracting most of the relevant biological and clinical
information from these data: (1) developing sufficiently powerful
computational architecture (software/hardware); (2) establishing
the organisational and management structure that is needed to
define the procedures for collecting high-quality data that is
reliable and traceable; and (3) developing scientific expertise to
create sophisticated mathematical models that can predict
the evolution of the disease and the risks to the patient (Barillot
et al, 2012).
Bioinformatics data analysis and recommendations for future
clinical data architecture. Clearly efficient informatics and
bioinformatics architecture is needed to support precision
medicine to record, manage, and analyse all of the collected
information. The architecture must also allow queries and the easy
retrieval of data that might be useful, either now or in the future,
for real-time therapeutic decisions so that clinicians can propose
tailored therapy to the patient without delays. Accordingly,
bioinformatics is among the most important bottlenecks in the
routine application of precision medicine. Several challenges must
be overcome to make precision medicine a reality. First, a seamless
information system must be developed that allows data integration,
data traceability, and knowledge sharing across the different
stakeholders. Second, bioinformatics pipelines need to be devel-
oped to make relevant biological information from the high-
throughput molecular profiles of the patient rapidly available to
clinicians. Third, the architecture must ensure the reproducibility
of the results. All of these bioinformatics challenges were reviewed
by Servant et al (2014). At the Institut Curie, in the context of the
RAIDs project, a information system termed KDI (for ‘knowledge
and data integration’) was set-up to ensure the sharing of
information between partners, cross-software interoperability,
automatic data extraction, and secure data transfer. Other similar
systems are available today, such as the tranSMART platform,
which is an open-source, community-driven knowledge manage-
ment platform for translational medicine (Barash et al, 2015).
CONCLUSION
In the era of precision medicine the numbers of biobanking studies
are increasing and raise several issues. The BIO-RAIDs study
identified challenges associated with the practical aspects of
systematic biobanking that lead to delays in clinical trial initiation.
To address these challenges, there needs to be increased
cooperation and standardisation in terms of regulatory rules and
practices across the EU. Although most errors are human errors
and related to initial handling, there is a need for teaching courses
for best-practice biobanking techniques standards and QC aspects.
On another level there is a need for a better understanding by
clinicians and by drug manufacturers of the technical and
bioinformatics analytical skills needed to improve decision-making
in the field of precision medicine. Although BIO-RAIDs is purely
an analytical trial, it sets the stage for future clinical trials of
specifically targeted drugs or drug cocktails. Ongoing work on cell
lines that compares mutational and proteomics data with
pharmacological profiling should help identify common targeted
drugs and drug cocktails that benefit patients. In addition to these
technical and clinical research aspects, the perception of patients
and their feedback on biobanking is key. A recent study shows that
patients are receptive to donate tissue samples if they are educated
on the importance of specimen based research (Braun et al, 2014),
an observation that seems to be shared in the BioRaids population.
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Table 5. Challenges in QC, data integration and data analysis
Challenges Specific challenges Recommendations
Biobank quality
analysis
Sample or data mixup Mixup can occurr at any step with a potential to falsify data.
(for example, error in barcode sticker, in date in eCRF as
compared with source data, laboratory mixup etc.)
Check for cross-contamination in each sample
and test for proper clustering of matched samples.
Clean and reliable data to be shared with other
platforms
Full exome
sequencing
Variant calling and
gene copy number
Choice of filters for variant callers and variant calling
parameters greatly influences the position of reported
variants in list of frequency
Establish a gold-standard variant caller pipeline that
shall be applied on all samples
Complex data
integration
Clinical and molecular
data integration
Bridge clinical with molecular data Implement of seemless integrating system
(ex. KDI TranSmarty)
Abbreviations: eCRF¼ electronic case report form; KDI¼ knowledge data integration; QC¼quality control.
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